MEK

Inhibitory Selectivity

Catalog No.	Inhibitor Name	MEK	MEK1	MEK1/2	MEK2	MEK5	Other
A10257	Selumetinib		***
A10256	PD0325901	****
A11029	Trametinib		****		****
A10957	U0126-EtOH		*		**		MKK6/p38 MAPK,MKK3/p38 MAPK
A10212	PD184352		**		**
A10705	PD98059		*
A10151	BIX 02189					****	ERK5,TGFβR1
A10089	Pimasertib			*
A10150	BIX 02188					***	ERK5,TGFβR1
A11040	TAK-733		****
A10115	AZD8330						ERK phosphorylation
A11493	Binimetinib	***		***
A14137	SL-327		*		*		AP-1,MKK3/p38 MAPK
A11264	Refametinib		**		**
A12974	GDC-0623		****
A15762	BI-847325		**		***		Aurora B,Aurora C,Aurora A
A11441	Cobimetinib		***
A10704	PD318088
A10453	Honokiol						Akt-phosphorylation
A11247	RO4927350
A13272	RO4987655	****
A14019	RO5126766 (CH5126766)		*				BRAF, CRAF

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
RO5126766 (CH5126766)

Catalog No. A14019
Quick View

添加到收藏
Raf/MEK dual 抑制剂

RO5126766 (CH5126766)是对Raf和MEK丝裂原激活的蛋白激酶（MAPK）具有特异性的蛋白激酶抑制剂，具有潜在的抗肿瘤活性。了解更多

Product Citations (1)

Bulk Inquiry
- Yuki Shimizu, .et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma, Cancer Lett, 2022, Sep 1;543 PMID: 35724767